Propanc Reports >90% Tumor Growth Inhibition In Preclinical Pancreatic Cancer Study; Shares Surge

Propanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.

Propanc Biopharma, Inc. (PPCB) shares rose about 26% after the company said it started a share repurchase program to buy a first tranche of up to $500,000 over 30 days. The stock was around $1.8150 on Nasdaq, up about 25.7% in the latest session.

Propanc Biopharma (PPCB) said its board approved a share repurchase program authorizing buybacks of up to $5.0 million of its common stock. The company expects the program to support shareholder ownership and improve per-share economics, citing management’s capital allocation approach. In pre-market trading, PPCB was at $2.87, up 114.23% on Nasdaq.

UBS analyst Karl Keirstead raised Palantir's (PLTR) price target to $250 from $220, citing strong demand and AI sovereignty trends observed at Palantir's AIPCon11 event. The new target implies 44% upside from the Sept. 14 closing price of $173. Keirstead highlighted Palantir's expanding commercial use and robust Q2 results, including $3.4B in bookings and a 157% net dollar retention rate. This is UBS's third upward revision this year, contrasting with the broader analyst consensus of a $194 aver

Meta (META) launched Muse, an AI agent that can manage emails, payments, and other tasks, with subscription plans ranging from free to $100/month. The agent is available in the U.S. and can access various apps, but faces internal concerns over data security and reliability. Meta expects over $130B in AI infrastructure spending this year, aiming to diversify revenue beyond advertising.

General Motors will produce parts for Patriot missiles for Lockheed Martin, according to the company. The move aims to address US munitions shortages amid prolonged conflict with Iran. The Pentagon seeks more manufacturers to accelerate procurement, with reports indicating significant depletion of missile interceptors and long-range missiles.